OUR FOCUS
At Paragon Biosciences our philosophy is simple: start with what the patient needs, understand the science behind the disease and then launch companies completely focused on addressing unmet needs. After early-incubation, the companies we launch operate independently. Our approach accelerates the approval of important medicines.
More than 7,000 diseases today do not have a treatment available. We will make that number smaller, and help patients live longer, better lives.
“Challenges which others have deemed unsolvable are the problems we are solving.”
- JEFFREY S. ARONIN
Portfolio Companies
Our investment portfolio of biopharmaceutical companies each specialize in a unique therapeutic area.
Castle Creek Pharma
Castle Creek Pharma employs a unique strategy in selective asset identification and capital efficient development that is driving the company to become one of the industry’s most prolific developers of innovative and high potential late stage therapies for rare genetic dermatology conditions. For more information, please visit www.castlecreekpharma.com.
INCUBATING
Decade Pharmaceuticals
Decade is a research and development company focused on novel Alzheimer’s disease therapeutics that will fundamentally improve patient outcomes and quality of life.
Emalex Biosciences
Emalex is committed to developing effective treatments for the Central Nervous System (CNS). Emalex’s focus is on making lives easier for the courageous people living with CNS disorders. For more information, please visit www.emalexbiosciences.com.
Evozyne
Evozyne is a world-leading company that creates novel proteins with exceptionally advanced functionality based on data-driven molecular engineering. Evozyne is working with some of the largest and most innovative companies to solve their pressing challenges. For more information, please visit www.evozyne.com.
Harmony Biosciences
Harmony Biosciences is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on therapies for sleep and cognitive disorders, Harmony’s goal is to push the boundaries of what science can do to improve the lives of patients. For more information, please visit www.harmonybiosciences.com.
INCUBATING
Immunogenix
Developing the latest therapies for those living with serious immunology conditions.
Qlarity Imaging
Qlarity Imaging improves patient care by building AI-driven products that provide clinical insights which radiologists do not have access to today. One of Qlarity’s initial products, QuantX Advanced, is the first FDA-cleared, computer-aided breast cancer diagnosis software for radiology. For more information, please visit www.qlarityimaging.com.
Skyline Biosciences
Skyline Biosciences is developing first in-kind oncology therapies to treat premalignant and malignant conditions with unmet medical need. Skyline’s mission is to alleviate potentially life-threatening conditions and to improve the quality of life for the patients it serves. For more information, please visit www.skylinebiosciences.com.
Pipelines of Our Portfolio Companies
Paragon's portfolio companies have a diverse pipeline of investigational drugs, in four therapeutic areas.
Our Process
We pride ourselves on investing in pharmaceutical compounds that our portfolio companies can develop into treatments for otherwise unmet patient needs. We embrace and overcome challenges to deliver important medicines.
